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Abstract
Background: Cardiovascular diseases are a main cause of mortality worldwide. Spa bathing and immersion in
thermoneutral water (ITW) have a long history in the treatment of cardiovascular risk factors.
Methods: We conducted a three-arm parallel-group, randomized controlled study to investigate the effects of
frequent ITW on moderately elevated blood pressure (BP). Here, we report on the secondary outcomes, i.e. the
influence of immersion in thermoneutral water on further cardiovascular risk factors: body mass index (BMI), waist
circumference, blood lipids, fasting blood glucose and C-reactive protein. Patients (age 57.6 ± 9.6 years, BMI 29.5 ± 5.
7 kg/m2) with mild to moderately elevated BP received ITW for 45–60 min in pools of thermal-mineral water at 34.
0–36.0 °C four times a week for 4 weeks. One group (Bath1) reduced the intensity to one bath a week for a further
20 weeks, while the other group (Bath2) continued bathing four times a week. The control group was instructed to
relax for 45–60 min four times a week for 24 weeks using a relaxation CD.
Results: The secondary analysis of the intention-to-treat population (N = 59) did not show a significant reduction of
BMI, waist circumference, blood lipids, fasting blood glucose or C-reactive protein in patients with a mild to
moderately elevated BP after 4 and 24 weeks ITW, respectively. There were no significant differences between the
groups.
Conclusion: Thus, we did not find evidence to support our ITW program being an efficacious intervention to
induce cardiovascular alterations in this population of hypertensive patients.
Trial registration: DRKS00003980 at drks-neu.uniklinik-freiburg.de, German Clinical Trials Register (registration date
2012-07-10).
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Background
Atherosclerotic cardiovascular disease (CVD) remains the
major cause of premature death in Europe, even though
CVD mortality has fallen considerably over recent decades
in many European countries. CVD is strongly associated
with lifestyle, especially the use of tobacco, unhealthy diet
habits, physical inactivity and psychosocial stress. The
World Health Organization (WHO) has stated that over
three-quarters of the deaths from CVD could be pre-
vented with adequate changes in lifestyle [1]. However, ad-
herence in real life to lifestyle modifications is poor, with
fewer than 50 % of patients practising any form of modifi-
cation at all [2, 3]. Thus, there is a strong need to find
treatment options that lead to better adherence to lifestyle
changes. With its long lasting history, both in the Eastern
and Western hemispheres, immersion in thermoneutral
water (ITW) or spa bathing may provide a treatment op-
portunity that meets wide acceptance and availability [4–6].
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During ITW, water pressure causes short-term cardio-
vascular responses as blood shifts from the legs and ab-
domen to the right atrium of the heart. ITW induces an
increase in stroke volume, a reduction of heart rate, an
increase of cardiac output, and a reduction of total per-
ipheral vascular resistance [7–9]. Furthermore, head-out
ITW has several advantages: Water reduces weight
bearing because of buoyancy, and water resistance
strengthens the muscles. In combination with aquatic
exercises, it provides obese and overweight people with
a noninjurious and easy to learn opportunity to lose
weight [10]. There is clinical evidence for a large antihy-
pertensive effect from exercise in thermoneutral water
[11, 12], and it is particularly important for lifestyle dis-
ease prevention as well as long-term care prevention,
and is prevalent among the middle-aged and elderly
population [13]. Balneotherapy and especially spa ther-
apy have also been studied for their possible metabolic
and anti-inflammatory effects, however the results are
inconsistent and scientific evidence is limited [14–18].
We therefore wished to address the question of
whether the positive effects on cardiovascular risk fac-
tors (CVRF) are mainly due to ITW or to the exercise
and other components of spa therapy. We have previ-
ously reported on the primary outcome of this study,
which did not show a significant reduction of blood
pressure (BP) in patients with mild to moderately ele-
vated BP after 4 and 24 weeks ITW [19]. Here, we report
on the secondary outcomes. We assumed that frequent
and regular use of ITW reduces CVRF in patients with
hypertension grade 1 and 2.
Methods
Study design and participants
This study is reported according to the CONSORT
guidelines for the presentation of clinical trials [20]. This
randomized, controlled, three-arm parallel-group study
was performed at the Interdisciplinary Center for Treat-
ment and Research in Balneology in Southern Germany.
Participants were recruited via announcement in local
newspapers and by sending written information about
the study to local physicians, hospitals and pharmacies.
Participants were eligible for inclusion if aged ≥ 18 years,
had a diagnosis of arterial hypertension with an office
systolic BP (SBP) of 140–180 mm Hg, and diastolic BP
(DBP) of 90–110 mm Hg (grade 1 and 2 hypertension
according to ESH/ESC guidelines 2013 [21]), had no
change of antihypertensive medication in the last four
weeks and no indication to change medication within
the next four weeks. Exclusion criteria were severe
disease - heart failure grade 3 or 4, peripheral arterial
disease grade 3 or 4, unstable angina, renal failure,
creatinine > 1.5 mg/dl - that might limit the patient’s
capacity to participate in the study or make other
treatments necessary, secondary hypertension, acute in-
fection, fever, reasons against use of public baths such as
open wounds, ITW (>1 per week) in the past two
months, pregnancy and participation in other interven-
tional studies. Written informed consent was obtained
from all the participants before inclusion; ethical ap-
proval was given by local Ethics Committee (Ethics-
Commission Medical Center University of Freiburg; No.
111/12). Clinical trial authorization was obtained from
the Federal Institute for Drugs and Medical Devices
(BfArM, Germany) and the Regional Council Freiburg.
The study was prospectively registered in the German
Clinical Trials Register (DRKS00003980) and conformed
to the principles of the Declaration of Helsinki and to
the GCP guidelines of the European Community.
Interventions
After completion of all baseline measurements partici-
pants were randomly allocated to one of two intervention
groups (Bath1, resp. Bath2) or the control group (relax-
ation). Both bathing groups started ITW (34.0–36.0 °C)
for 45–60 min four times a week for four weeks. Treat-
ment locations were three spa centers in South-West
Germany (Bad Krozingen, Freiburg and Bad Bellingen)
with a comparable water mineral content (see Additional
file 1: Table S1) and temperature. All participants were
instructed to have head-out ITW (minimum deeper than
axilla). After 4 weeks, one bathing group (Bath2) contin-
ued with four baths a week for another 20 weeks, while
the other bathing group reduced to one bath a week
(Bath1). The control group was advised to practice relax-
ation at home four times a week for 45–60 min for
24 weeks. Patients were provided with a relaxation CD,
teaching them progressive muscle relaxation according to
Jacobson, with some elements of awareness produced by
RH to treat his patients. All groups were given written
information on non-pharmacological methods to reduce
BP edited by [22] and were advised to follow the
instructions.
Outcome measures: CVD parameters and blood
biochemistry
The primary outcome was BP measured after 4 and
24 weeks ITW, respectively, and has been reported pre-
viously [19]. Here, we report on the secondary clinical
outcomes of CVRF: BMI, waist circumference, blood
lipids, fasting blood glucose and C-reactive protein
(CRP). Body weight was measured by using a digital
scale (Soehnle professional, no. 7701; self-calibrating),
height was measured by using a telescopic mechanical
height rod (Seca, no. 2251721009), waist circumference
was measured at the umbilical level using an inelastic
measuring tape on the bare skin and recorded to the
nearest 0.1 cm. The tape was snugged horizontally
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around the abdomen passing across the umbilicus with-
out causing compression on the skin. Measurement was
performed at the end of normal expiration. Blood samples
were collected for total cholesterol, high-density lipoprotein
(HDL) cholesterol, low-density lipoprotein (LDL) choles-
terol, triglyceride and CRP (all measured in serum, centri-
fuged 30 min after taking blood) and fasting blood glucose
(NaF-Plasma). Analyses were done at the Institut für
Klinische Chemie und Laboratoriumsmedizin (IKCL), Med-
ical Center University of Freiburg (certified by Deutsche
Akkreditierungsstelle DAkkS according to ISO 9001:2008).
Randomization and blinding
Randomization codes (single block of 60 patients) were
generated by an independent statistician (SS). Because sev-
eral participants withdrew consent after randomization but
before being informed about their allocation, a further six
participants were randomized in a single block. Enrolment
(JN) was done directly after informed consent was obtained
from the patients. Study IDs were assigned chronologically.
In order to conceal allocation, SS was informed and added
the study ID in chronological order in the randomization
list. SS had no interaction at all with the patients. On their
next visit, patients received a sealed, opaque envelope
informing them of their allocated treatment.
Statistical analyses and sample size
Efficacy parameters were analyzed based on the intention-
to-treat (ITT) population, defined as all allocated partici-
pants, applying the last-observation-carried-forward
(LOCF) approach to impute missing data. Baseline differ-
ences between the three groups were assessed by either
univariate analyses of variance (ANOVA) or by Chi2 tests.
To compare the effectiveness of ITW, a one-way between-
groups analysis of covariance (ANCOVA) was conducted.
The analysis model was built with group allocation as the
independent variable, BMI, waist circumference, blood
lipids, fasting blood glucose and CRP as the dependent
variables, and the corresponding baseline scores as covari-
ates. Prior to the analysis, we made sure that the specific
assumptions for normality and homogeneity of variance
for the one-way ANCOVA were met.
We report P-values and the respective partial eta2 as
effect size. A sample size calculation was performed for
the primary outcome BP and resulted in 20 patients per
group. Analyses were performed using SPSS version 20
(SPSS, Chicago IL). Data management and analyses were
performed blinded to treatment allocation (SS, TW).
Results
Study population
Details of participant flow are given in the figure (Fig. 1).
During enrolment between July 2012 and April 2013, we
screened 1085 patients. Of this number, 1019 participants
were excluded - 701 for not fulfilling the inclusion criteria
(mainly not having elevated BP values) and 318 for various
other reasons such as not accepting randomization to
regular baths or no baths for 6 months. In the end, a total
of 66 participants met the inclusion criteria and were ran-
domized into the study. Of these, seven withdrew their
consent before receiving their allocation and were ex-
cluded from ITT-analysis, resulting in a final sample of 59
participants. According to Fergusson et al. [23], this so-
called post-randomization exclusion from the primary ana-
lysis may be legitimate if patients have not received the
intervention. In this case, excluding patients does not intro-
duce bias and may lead to a more informative analysis.
Baseline details for the 59 participants allocated into the
study are shown in Table 1. All participants were of Cauca-
sian background, mostly overweight (BMI 29.5 ± 5.7 kg/m2)
and medium age was 57.6 ± 9.6 years. Thirty-three patients
(55.9 %) were taking antihypertensive medication (i.e. ACE
inhibitors, AT1-receptor antagonists, diuretics, Calcium-
antagonists) see Additional file 2: Table S2. There were no
statistically significant differences at baseline between the
study groups in age, BMI, BP or CVRF. There were statis-
tically significant differences at baseline between the
study groups in fasting blood glucose (Bath1: 110,
Bath2: 90, Control: 95 mg/dl; PBath1 x Bath2 = 0.02),
gender (PBath1 x Bath2 = 0.04), and the use of antihy-
pertensive medication (Bath1: 57.9 %, Bath2: 33.3 %,
Control: 78.9 %; PBath2 x Control = 0.02) (for details see
Additional file 2: Table S2).
Safety, tolerability and compliance
Six (10.2 %) participants dropped out during the study,
two in Bath1, one in Bath2 and three in the control
group. The alleged reasons for leaving the study were
discontent with the assigned group (n = 3) and adverse
events. In group Bath1 there was one serious adverse
event (apoplexy that occurred in a patient with preexist-
ing cerebral apoplexy who had reduced the frequency of
baths) and one adverse event (superficial thrombophle-
bitis). After a bicycle accident one participant from the
control group discontinued the study. In any case there
was no association between drop-out and treatment
(ITW/relaxation).
A further 34 non-treatment-related adverse events were
reported by 25 patients - 20 common colds, one nasal
bleeding, two headaches, one lumbago, three gastrointes-
tinal disturbances, one cystitis, one sore throat, one gastric
ulcer, one temporary itching of the legs, two cases of feel-
ing unwell without specific complaints and one atrial
fibrillation that was converted into sinus rhythm with
bisoprolol. Two changes in antihypertensive treatment
were recorded. One participant stopped medication (rami-
pril), and one (with new diagnosis of atrial fibrillation)
started medication (bisoprolol). Adherence to therapy
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(Table 2) was good, with 77 % of the participants taking
more than 75 % of the recommended number of baths in
the intense bathing group (Bath2) and 89 % in the less in-
tense bathing group (Bath1). None of the patients were
lost to follow-up.
Data monitoring
Data monitoring was done blind to treatment allocation,
with double data entry by two independent persons for
20 % of the values (revealing one error in 1776 data cases).
Effects of treatment on CVRF
Table 3 shows the effects of head-out ITW (Bath1,
Bath2) or relaxation (Control) on BMI, waist circumfer-
ence, blood lipids, fasting blood glucose and CRP. The
mean (SD) BMI at baseline was 30 (5) (Bath1), 27 (5)
(Bath2) and 31 (6) (Control). After 24 weeks, corre-
sponding values were 29 (5) (Bath1), 27 (6) (Bath2) and
31 (6) (Control) (P = 0.30, partial eta2 0.04). No signifi-
cant differences were observed between the groups in
waist circumference, blood lipids, fasting blood glucose
and CRP. At the end of treatment one out of nine
Fig. 1 CONSORT 2010 Flow Diagram
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smokers (11 %) had stopped smoking (Bath1), two had
reduced (Bath2 n = 1; Control n = 1).
Discussion
Compared to a control group using regular relaxation tech-
niques, intense ITW (one or four times a week) over a 24-
week period did not reduce CVRF after either 4 or
24 weeks, respectively. This result was unexpected and sev-
eral possibilities merit discussion to explain our findings.
Intensity
The intensity of ITW used does not explain our negative
results, because we investigated high and low intensity
ITW.
Temperature
High temperature (≥37.0 °C) causes more vasodilation
and enhances metabolism, the temperature of the water
(34.0–36.0 °C) may therefore have been too low. However,
there is only little evidence for a cardiovascular influence
and the results are inconsistent. In a small trial with eight
patients with diabetes mellitus type 2 [24] bathing in hot
tubs at 38.0–40.0 °C for 30 min per day, six times per
week for three weeks resulted in a mean weight loss of
1.7 kg, and a decrease of fasting blood glucose from
182 mg/dl to 159 mg/dl. A Japanese RCT using hot baths
(40.0 °C; 20 min once a fortnight) found no significant ef-
fect on BMI, waist circumference, serum lipids or blood
glucose in healthy subjects [25]. A Hungarian study found
Table 1 Baseline demographic and clinical characteristics of the intention-to-treat population (N = 59)
Overall N = 59 Bath1 N = 19 Bath2 N = 21 Control N = 19 P
Gender (female/male) 29/30 5/14 14/7 10/9 0.04*a
Age (years) 57.6 (9.6) 60.2 (6.7) 57.1 (10.0) 55.5 (11.4) 0.32
Patients taking antihypertensive medication (n) 33 (55.9 %) 11 (57.9 %) 7 (33.3 %) 15 (78.9 %) 0.02*a
No CVRF (n) 2 0 2 0 0.46a
1–2 CVRF (n) 32 9 13 10
≥3 CVRF (n) 22 9 5 8
CVD (n) 3 1 1 1
Smoking status (smoker/non-smoker) 9/50 (15 %) 1/18 (5 %) 4/17 (19 %) 4/15 (21 %) 0.33a
SBP (mm Hg) 145.2 (10.2) 147.2 (7.8) 143.8 (12.3) 144.8 (9.9) 0.55
DBP (mm Hg) 90.1 (8.5) 91.8 (8.4) 90.5 (9.9) 88.1 (7.0) 0.42
BMI (kg/m2) 29.5 (5.7) 29.9 (5.3) 27.4 (5.3) 31.3 (5.9) 0.08
Waist circumference (cm) 102.0 (13.0) 106.0 (14.0) 98.0 (13.0) 103.0 (11.0) 0.20
Cholesterol total (mg/dl) (50–200) 226.0 (36.0) 219.0 (38.0) 230.0 (35.0) 227.0 (36.0) 0.63
LDL (mg/dl) (<160) 138.0 (33.0) 135.0 (33.0) 143.0 (31.0) 137.0 (35.0) 0.72
HDL (mg/dl) (>40) 48.0 (15.0) 47.0 (13.0) 51.0 (15.0) 44.0 (15.0) 0.28
LDL/HDL Quotient (<3) 3.2 (1.3) 2.9 (0.9) 3.1 (1.5) 3.5 (1.5) 0.38
Triglyceride (mg/dl) (<150) 153.0 (88.0) 168.0 (107.0) 126.0 (56.0) 168.0 (95.0) 0.22
CRP (mg/l) (0–5) 2.7 (2.3) 2.5 (2.3) 2.3 (2.3) 3.3 (2.3) 0.36
Fasting blood glucose (mg/dl) (70–110) 99.0 (23.0) 110.0 (30.0) 90.0 (18.0) 95.0 (15.0) 0.02*
Data are shown as mean and standard deviation (SD)
*P < 0.05
BMI body mass index, CVRF cardiovascular risk factors, CVD cardiovascular disease, SBP systolic blood pressure, DBP diastolic blood pressure, CRP C-reactive protein
aChi2-test
Table 2 Adherence to therapy and bath frequency
n Frequency Target Frequency Actual Adherence (%) >75 % Adherence (n)
Week 1–4 Bath 1 19 16 15 94
Bath 2 21 16 14 88
Week 5–24 Bath 1 19 20 18 90
Bath 2 21 80 57 71
Total Bath 1 19 36 32 89 16
Bath 2 21 96 74 77 9
Week 1–4: bathing four times a week (Bath 1, Bath 2)
Week 5–24: bathing once a week (Bath 1); bathing four times a week (Bath 2)
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no significant reduction in plasma lipids or CRP in 42 am-
bulatory patients with degenerative musculoskeletal dis-
ease after 15 baths at 38.0 °C over 3 weeks compared to
baseline [16].
Exercise
It may also be necessary to combine ITW (32.0 °C) with
exercise. This was shown in a 12-week randomized con-
trolled trial in which a large significant reduction of BP
(office SBP −36 mm Hg, DPB −12 mm Hg; 24-h ambula-
tory SBP −17 mm Hg, DBP −9 mm Hg) was observed in
patients with resistant hypertension [12]. In a 10-week
study (water aerobic training program using 55 min ses-
sions 3 days per week) with 40 hypertensive men (grade
1 and 2), a reduction of SBP of 11.71 mm Hg and of
DBP of 5.9 mm Hg compared to baseline was observed
[11]. It appears that the exercise component is even
more important than immersion; at least, this is what a
randomized controlled study with 52 post-menopausal
hypertensive women, which found no difference between
the effect of water-based exercise compared to land-
based exercise suggests [26].
Complex therapies
It may also be necessary to combine ITW with more
complex therapies such as spa therapies. A 3-week Zelen
double consent randomized controlled trial (N = 257) in
France [27] found that a complex spa therapy with ITW
(daily bubble bathing, water manual massages, mud
therapy, water pool exercise, drinking of mineral water,
nutrition and physical activity counseling) significantly
reduced BMI (mean BMI loss after 14 months follow-up
was 1.91 kg/m2 [95 % CI: 1.46; 2.35]; P < 0.001). In a ran-
domized, controlled trial from Poland [28] 50 overweight
and obese patients (BMI = 43.8) presented a significant
weight reduction with an average loss of 7 % of their
Table 3 Effect of ITW on cardiovascular risk factors (CVRF) after 24 weeks; mean (SD), intention-to-treat population (N = 59)
CVRF Group Baseline Week 4 Week 24 Change Baseline/Week 24 P Value Partial eta2
BMI (kg/m2) Bath 1 29.9 (5.3) 29.5 (5.0) 29.3 (4.9) −0.6 (3.2)
Bath 2 27.4 (5.3) 27.5 (5.5) 27.2 (5.8) −0.2 (3.5) 0.30 0.04
Control 31.3 (5.9) 31.5 (5.9) 31.1 (5.7) −0.2 (3.7)
Waist circumference (cm) Bath 1 105.5 (13.6) 103.7 (13.8) 104.1 (12.8) −1.4 (8.4)
Bath 2 98.4 (12.7) 98.9 (14.6) 98.2 (15.6) −0.2 (9.4) 0.69 0.01
Control 102.5 (10.7) 102.3 (9.9) 101.8 (10.7) −0.7 (6.8)
Cholesterol total (mg/dl) (50–200) Bath 1 219.4 (38.2) 215.2 (32.3) 211.1 (34.6) −8.3 (23.3)
Bath 2 230.2 (35.0) 233.1 (32.4) 236.6 (47.3) 6.4 (28.5) 0.09 0.09
Control 226.9 (35.6) 212.9 (33.3) 222.2 (34.4) −4.7 (22.2)
LDL (mg/dl) (<160) Bath 1 134.5 (33.3) 135.7 (29.1) 129.9 (27.0) −4.6 (20.0)
Bath 2 143.0 (30.6) 144.9 (25.7) 147.2 (32.7) 4.2 (20.1) 0.13 0.09
Control 136.8 (35.1) 128.9 (34.2) 141.7 (34.3) 4.9 (22.0)
HDL (mg/dl) (>40) Bath 1 47.3 (13.1) 47.0 (15.3) 45.8 (11.0) −1.5 (7.9)
Bath 2 51.4 (14.7) 52.8 (14.2) 51.1 (15.1) −0.3 (9.4) 0.84 0.01
Control 44.0 (15.2) 45.8 (13.6) 45.9 (15.5) 1.9 (9.7)
LDL/HDL Quotient (<3) Bath 1 2.9 (0.9) 3.1 (1.0) 3.0 (0.9) 0.1 (0.6)
Bath 2 3.1 (1.5) 2.9 (0.9) 3.0 (1.0) −0.1 (0.9) 0.39 0.04
Control 3.5 (1.5) 3.1 (1.4) 3.6 (1.9) 0.1 (1.1)
Triglyceride (mg/dl) (<150) Bath 1 168.0 (107.0) 146.0 (77.0) 126.0 (42.0) −42.0 (77.6)
Bath 2 126.0 (56.0) 134.0 (66.0) 121.0 (56.0) −5.0 (35.4) 0.77 0.01
Control 168.0 (95.0) 149.0 (68.0) 144.0 (57.0) −24.0 (60.1)
CRP (mg/l) (0–5) Bath 1 2.5 (2.3) 1.6 (1.3) 1.6 (1.3) −0.9 (1.5)
Bath 2 2.3 (2.3) 1.8 (1.9) 2.3 (2.7) 0.0 (1.6) 0.64 0.02
Control 3.3 (2.3) 2.5 (2.3) 2.4 (2.5) −0.9 (1.5)
Fasting blood glucose (mg/dl) (70–110) Bath 1 110.0 (30.0) 101.0 (24.0) 104.0 (26.0) −6.0 (18.1)
Bath 2 90.0 (18.0) 91.0 (12.0) 88.0 (8.0) −2.0 (12.6) 0.55 0.03
Control 95.0 (15.0) 90.0 (15.0) 93.0 (15.0) −2.0 (9.5)
Analysis of covariance (ANCOVA) with baseline values as covariates. P-value and partial eta2 refer to time × group interaction
BMI body mass index, CRP C-reactive protein, HDL high-density lipoprotein, ITW immersion in thermoneutral water, LDL low-density lipoprotein
Naumann et al. BMC Complementary and Alternative Medicine  (2016) 16:250 Page 6 of 8
initial weight and other CVRF such as total cholesterol,
LDL-cholesterol, triglycerides and blood glucose after a
3-week spa therapy consisting of 15 daily mineral (4 %
NaCl) thermal baths (31.0 °C) in a swimming pool and
mud packs and a 1000 kcal diet. Similar results were shown
in a 3-week non-randomized, controlled trial (N = 199) with
ITW as part of complex spa therapy (cardiopulmonary en-
durance training, individually adjusted diet, education
programme on CVRF and physical and balneological
treatment related to other diseases). The spa therapy
significantly reduced BMI (P < 0.001), mean arterial
BP (P = 0.002), apolipoprotein B (P = 0.015), fasting in-
sulin (P = 0.035) and fibrinogen (P = 0.950) [18].
In our study, ITW was combined with written infor-
mation about a healthier lifestyle. We expected high mo-
tivation or adherence to a healthier lifestyle. However,
this intervention did not seem to be intense enough.
This may be explained by the fact that the participants
relied completely on the effects of ITW or the relaxation
technique. Another explanation for the minimal effect
over time in all three treatment groups may be that un-
specific effects such as regression to the mean were min-
imized in our trial, as there was a 1-week gap between
the time of inclusion and baseline. One trial in Germany
investigating spa therapy including ITW in mineral
water found that 50 % of the moderate effects on CVRF
happened during the first day of treatment [29].
Study limitation
The strengths of our study include the randomized, con-
trolled design, blinded statistical analyses and data man-
agement. The outcome parameters were measured
independently and were not influenced by the outcome
assessor (JN). Limitations include the relatively small
study size, the absence of supervision in the ITW groups
(Bath1, Bath2) and the control group (relaxation), and,
most importantly, the absence of blinding in the treat-
ment groups, which is inherent and inevitable, due to
the active participation required by the study partici-
pants. As recruitment via physicians (primary care cen-
ters), hospitals and pharmacies was difficult (n = 4
patients), the majority of patients was recruited via pub-
lic announcement. Therefore we had to screen many
non-hypertensive patients, respectively well-controlled
patients, who hoped to reduce their medication during
the trial. This resulted in >1000 screened patients, how-
ever, from our point of view not resulting in a relevant
bias. The drop-out rate was relatively low, taking into
account the intensive treatment with four ITW-sessions
per week. Nevertheless, it was still about 10 % (6/59).
Due to the small number of participants, subgroup ana-
lyses were not performed (i.e. different antihypertensive
medication vs. no medication).
Generalizability
Although external validity may be restricted due to the
population selected to participate in clinical studies, the
population studied here can be regarded as representa-
tive of routine clinical practice, including patients with
and without antihypertensive medication [30]. We had
only few exclusion criteria and 63 % (37/59) of our study
population comprised regularly working people (>3 h/d).
We had expected a higher percentage of non-working
people (pensioners, housewives) as four baths a week are
quite time-consuming.
Clinical implications
ITW alone cannot be recommended as adjuvant therapy to
reduce CVRF in hypertensive patients grade 1 and 2. As
shown in other studies, it may be important to combine
ITW with aquatic exercise, which seems to be effective in at
least reducing elevated BP, or other balneological therapies.
Conclusions
It seems eminently important to combine ITW with
other treatments for lifestyle change such as complex
balneotherapy, diet, physical activity, or at least appro-
priate counseling. Further evaluation in rigorously de-
signed clinical studies will be necessary to validate the
impact of balneotherapy on CVRF.
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